Skip Navigation LinksHome > May 2012 - Volume 28 - Issue 3 > Hepatitis C therapy update
Current Opinion in Gastroenterology:
doi: 10.1097/MOG.0b013e3283528e1e
LIVER: Edited by Don Rockey

Hepatitis C therapy update

Casey, Lisa C.; Lee, William M.

Collapse Box


Purpose of review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field.

Recent findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy.

Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Readers Of this Article Also Read